Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7WKTM)

• Drug Name: SLV-338 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM7WKTM

Molecule-Related Drug Atlas

Drug(s) Targeting Neutral endopeptidase (MME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LCZ696	DMLFX7K	Heart failure	BD10-BD13	Approved	[2]
Candoxatril	DMHJCGV	Hypertension	BA00-BA04	Phase 3	[3]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[4]
SLV 306	DMCDON3	Acute decompensated heart failure	BD1Z	Phase 2	[5]
SLV-334	DMXCJKY	Brain injury	NA07.Z	Phase 2	[6]
VX-15	DMLWM4G	Huntington disease	8A01.10	Phase 2	[7]
Sampatrilat	DMXTOVE	Hypotension	BA20-BA21	Phase 2	[8]
GW-796406	DMQ46DN	Hypotension	BA20-BA21	Phase 1	[4]
Debio 0827	DMQIEFB	Chronic pain	MG30	Phase 1	[9]
CART-10 cells	DMQ4UJ6	Acute lymphoblastic leukaemia	2A85	Phase 1	[10]

Drug(s) Targeting Endothelin-converting enzyme (ECE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SLV 306	DMCDON3	Acute decompensated heart failure	BD1Z	Phase 2	[5]
SLV-334	DMXCJKY	Brain injury	NA07.Z	Phase 2	[6]
WS-75624B	DM89BA1	Cardiovascular disease	BA00-BE2Z	Terminated	[11]
SM-19712	DMNX93E	Hypertension	BA00-BA04	Terminated	[12]
Phosphoramidon	DM3VL7G	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Endothelin-converting enzyme (ECE)	TT1BGDH	NOUNIPROTAC	Modulator	[1]
Neutral endopeptidase (MME)	TT5TKPM	NEP_HUMAN	Modulator	[1]

References

• [1] Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
• [2] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [3] Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
• [4] Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
• [5] The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
• [6] Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
• [9] Clinical pipeline report, company report or official report of Debiopharm (2011).
• [10] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [11] WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. II. Structure elucidation of WS75624 A and B. J Antibiot (Tokyo). 1995 Oct;48(10):1073-5.
• [12] Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats. Jpn J Pharmacol. 2000 Sep;84(1):16-24.
• [13] In vitro enzymatic processing of radiolabelled big ET-1 in human kidney. Biochem Pharmacol. 1998 Mar 1;55(5):697-701.